Pricing Log in Create free account
Tuesday 20 October 2026 Export INCY’s income statement to Excel — free account

Incyte Corporation

INCY Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.

115.09 1.84 +1.62%
Market cap
$23.0B
P/E
13.9×
Fwd P/E
58.4×
Dividend yield
—
F-score
9/9
Altman Z
8.57
Beneish M
−2.43
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Incyte Corporation (INCY) P/B ratio

Alert me on P/B ratio

As of 19 October 2026, Incyte Corporation (INCY) trades at a P/B ratio of 3.6×. Over the past ten years it has ranged from 0.0× (June 2015) to 426× (September 2015); the current reading is higher than 19% of that period. That is above the Biotechnology industry median of 2.2× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 3.7× (10.08%)
FY2024 4.1× 47.13%
FY2023 2.8× (30.21%)
FY2022 4.0× (5.83%)
FY2021 4.3× (40.92%)
FY2020 7.3× 0.58%
FY2019 7.2× 2.99%
FY2018 7.0× (44.60%)
FY2017 12.7× (72.38%)
FY2016 45.8× (59.73%)

Quarterly newest first

Period P/B ratio Change
Jun 2026 3.6× 7.30%
Mar 2026 3.3× (10.57%)
Dec 2025 3.7× 4.57%
Sep 2025 3.6× 12.64%
42 more quarters

Against its own ten years

Low 0.0× High 426×
Ten-year median 6.3×
Current reading's percentile 16

P/B ratio against peers

Company P/B ratio
BNTX BioNTech SE Sponsored ADR compare 1.1×
RPRX Royalty Pharma PLC compare 2.7×
INCY Incyte Corporation 3.6×
GMAB Genmab A/S Sponsored ADR compare 4.0×
ROIV Roivant Sciences Ltd. compare 5.1×
EXEL Exelixis, Inc. compare 8.5×
ASND Ascendis Pharma A/S compare 8.9×
ALNY Alnylam Pharmaceuticals, Inc. compare 23.0×
INSM Insmed, Inc. compare 27.4×
Biotechnology industry median 2.2×
Healthcare sector median 2.3×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on INCY